Starten Sie Ihre Suche...


Wir weisen darauf hin, dass wir technisch notwendige Cookies verwenden. Weitere Informationen
Publikationen
Ergebnisse pro Seite:  10

Ugurel, Selma; Schmidberger, Heinz

New trends in melanoma From adjuvant therapy in stage II to novel treatment strategies with ImmTACs

ONKOLOGIE. Bd. 29. H. 8. 2023 S. 656-659




Hasenburg, Annette; Blohmer, Jens-Uwe; Janni, Wolfgang et al.

Oncology - Dose-intensive training in gynecological oncology - AGO State of the Art 2023

GEBURTSHILFE UND FRAUENHEILKUNDE. Bd. 83. H. 10. 2023 S. 1179-1183


Pfisterer, Jacobus; Joly, Florence; Kristensen, Gunnar et al.

Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial

JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. H. 4. 2023 S. 893-+


Hartmann, Ann-Kathrin; Bartneck, Joschka; Pielenhofer, Jonas et al.

Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection

FRONTIERS IN IMMUNOLOGY. Bd. 14. 2023


Musoro, Jammbe Z.; Coens, Corneel; Sprangers, Mirjam A. G. et al.

Original Research Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types

EUROPEAN JOURNAL OF CANCER. Bd. 188. 2023 S. 171-182


Schubert, Maria-Luisa; Bethge, Wolfgang A.; Ayuk, Francis A. et al.

Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study

BLOOD ADVANCES. Bd. 7. H. 20. 2023 S. 6191-6195



Sonneveld, Pieter; Chanan-Khan, Asher; Weisel, Katja et al.

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. H. 8. 2023 S. 1600-+